NGD-4715
From Self-sufficiency
| File:NGD-4715 structure.png | |
| Systematic (IUPAC) name | |
|---|---|
|
1-(3,4-dimethoxybenzyl)-4-(5-bromo-6-methoxypyridin-2-yl)piperazine | |
| Chemical data | |
| Formula | C19H24BrN3O3 |
| Molar mass | 422.315[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
NGD-4715 is a drug being developed by Neurogen, which acts as a selective, non-peptide antagonist at the melanin concentrating hormone receptor MCH1. In animal studies it has anxiolytic, antidepressant and anorectic effects,[1] and it has successfully passed Phase I clinical trials in humans.[2]
 |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />- Jump up ↑ Chaki S, Kanuma K. Neuropeptide receptors: Novel therapeutic targets for depression and anxiety disorders. Drugs of the Future. 2007;32(9):809.
- Jump up ↑ Neurogen Announces Results of First-in-Human Trial for New Approach to Treating Obesity. Business Wire. May 2 2007
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Pharmacology stubs
- 2Fix
- Antidepressants
- Anxiolytics
- Anorectics
- Piperazines
- Pyridines
- Organobromides
- Phenol ethers
